Patents by Inventor Elisabete Goncalves

Elisabete Goncalves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE
    Publication number: 20220249498
    Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
    Type: Application
    Filed: December 15, 2021
    Publication date: August 11, 2022
    Inventors: Elisabete GONCALVES, Christin TAUCHMANN, Sudha VIPPAGUNTA, Shau-Fong YEN, Zhixin ZONG
  • Tablet Formulation of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl) Imidazo [1,2-B] [1,2,4] Triazin-2-YL] Benzamide
    Publication number: 20210113569
    Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
    Type: Application
    Filed: February 13, 2020
    Publication date: April 22, 2021
    Inventors: Elisabete Goncalves, Christin Tauchmann, Shau-Fong Yen, Sudha Vippagunta, Zhixin Zong
  • Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
    Patent number: 10596178
    Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Novartis AG
    Inventors: Elisabete Goncalves, Christin Tauchmann, Shau-Fong Yen, Sudha Vippagunta, Zhixin Zong
  • Pharmaceutical compositions
    Patent number: 10188696
    Abstract: The invention provides lipid-based pharmaceutical compositions comprising alisporivir.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: January 29, 2019
    Assignees: Novartis AG, Debiopharma S.A.
    Inventors: Elisabete Goncalves, Karin Rapp, Bertrand Sutter, Frank Stowasser, Bjoern Trupp, Sebastian Chabaut, Julien Thorens
  • Tablet Formulation of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl) Imidazo [1,2-B] [1,2,4] Triazin-2-YL] Benzamide
    Publication number: 20190015418
    Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
    Type: Application
    Filed: September 18, 2018
    Publication date: January 17, 2019
    Inventors: Elisabete Goncalves, Christin Tauchmann, Shau-Fong Yen, Sudha Vippagunta, Zhixin Zong
  • Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
    Patent number: 10085993
    Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: October 2, 2018
    Assignee: Novartis AG
    Inventors: Elisabete Goncalves, Christin Tauchmann, Shau-Fong Yen, Sudha Vippagunta, Zhixin Zong
  • Tablet Formulation Of 2-Fluoro-N-Methyl-4-[ 7- ( Quinolin-6-Ylmethyl) Imidazo [1,2-B] [1,2,4] Triazin-2-YL] Benzamide
    Publication number: 20170231997
    Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
    Type: Application
    Filed: July 22, 2015
    Publication date: August 17, 2017
    Applicant: Novartis AG
    Inventors: Elisabete Goncalves, Christin Tauchmann, Shau-Fong Yen, Sudha Vippagunta, Zhixin Zong
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20160367624
    Abstract: The invention provides lipid-based pharmaceutical compositions comprising alisporivir.
    Type: Application
    Filed: May 12, 2016
    Publication date: December 22, 2016
    Applicants: Novartis AG, DEBIOPHARM S.A.
    Inventors: Elisabete Goncalves, Karin Rapp, Bertrand Sutter, Frank Stowasser, Bjoern Trupp, Sebastian Chabaut, Julien Thorens
  • Stabilized Amorphous Forms of Imatinib Mesylate
    Publication number: 20140323495
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: July 15, 2014
    Publication date: October 30, 2014
    Applicant: NOVARTIS AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20140005123
    Abstract: The invention provides lipid-based pharmaceutical compositions comprising alisporivir.
    Type: Application
    Filed: December 12, 2011
    Publication date: January 2, 2014
    Applicants: DEBIOPHARM S.A., NOVARTIS AG
    Inventors: Elisabete Goncalves, Karin Rapp, Bertrand Sutter, Frank Stowasser, Bjoern Trupp, Sebastian Chabaut, Julien Thorens
  • Stabilized Amorphous Forms of Imatinib Mesylate
    Publication number: 20130225598
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-pheny]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: April 17, 2013
    Publication date: August 29, 2013
    Applicant: Novartis AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
  • Stabilized Amorphous Forms of Imatinib Mesylate
    Publication number: 20130022672
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of lmatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: September 24, 2012
    Publication date: January 24, 2013
    Applicant: NOVARTIS AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
  • STABILIZED AMORPHOUS FORMS OF IMATINIB MESYLATE
    Publication number: 20100178336
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N--[4-methyl-3-( 4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: June 5, 2008
    Publication date: July 15, 2010
    Applicant: NOVARTIS AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100022565
    Abstract: Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone.
    Type: Application
    Filed: February 29, 2008
    Publication date: January 28, 2010
    Inventors: Thomas Buhl, Elisabete Goncalves, Oskar Kalb, Lorenz Meinel, Sibylle Reidemeister, Agnes Taillardat, Leo Widler